The present invention concerns methods and compositions for gene therapy, in particular in vivo gene therapy for delivery of bioactive glial derived neurotrophic factor (GDNF) for the treatment of Parkinson's Disease. The invention also concerns mammalian cells capable of producing GDNF in increased amounts as well as the use of these cells for recombinant production of bioactive GDNF and for therapeutic use. The invention also includes a device that may be implanted in the cochlear of a patient that is capable of secreting GDNF.

Provided herein is technology relating to engineered tissues and particularly, but not exclusively, to methods, compositions, and systems for engineering a biosynthetic vascular network.

The present invention is directed to a method of preparing an artificial tooth primordium in vitro, comprising the steps: a) providing isolated mesenchymal dental pulp cells; and b) culturing the mesenchymal dental pulp cells under non-adherent conditions to form a cell aggregate representing an artificial tooth primordium; as well as to an artificial tooth primordium derived therefrom.

Embodiments of the present disclosure encompass systems and methods for in-situ/in vivo, bottom-up tissue generation for wound repair, repair of tissue defects, and the like. Embodiments of the systems of the present disclosure include modular scaffolds seeded with cells (modular tissue forming units (MTFUs)) for packing a tissue defect, such that these MTFUs are able to fill the wound bed with cells of one or more needed tissue types supported by the modular scaffolding particles.

The invention provides method for preparing amnion tissue grafts, as well as the grafts themselves. In specific embodiments, the tissue graft comprises a single layer of dried amnion from an umbilical cord.

The present disclosure relates to compressed bone compositions, bone implants, and variants thereof. The present disclosure also relates to methods of preparing compressed bone compositions, bone implants, and variants thereof. The present disclosure also relates to methods of using the bone compositions, bone implants and variants thereof.

The disclosure provides a method for producing hepatocytes or hepatic progenitor cells; a method for suppressing hepatocyte aging using a drug causing histone hyperacetylation; a hepatocyte anti-aging agent; a method for increasing hepatocyte plasticity; and a drug for increasing hepatocyte plasticity.

The present disclosure provides a bioprinting system (100) for printing a liquid directly onto a subject. The bioprinting system (100) comprises a bioprinting assembly (102). Optionally, a robotic arm (104) and a control system (150) are provided. The bioprinting assembly (102) may be coupled to the robotic arm (104) to be positionable relative to the subject. The bioprinting assembly (102) is configured to dispense the liquid onto the subject and comprises a reservoir (120) for holding the liquid and a loading mechanism (134) to prime the reservoir (120) with the liquid directly prior to printing. The loading mechanism (134) has a one way inlet to permit liquid to be loaded into the reservoir (120) and prevent fluid from exiting the reservoir via the one way inlet. There is also provided associated methods.

The present invention relates to a fibrocartilage preparation method and fibrocartilage prepared by the method.

The disclosure relates to novel compositions comprising 1) conditioned media, 2) combinations of secreted biomolecules/organic molecules, and/or 3) secreted extracellular vesicles/exosomes collected from differentiated epithelial cell culture, as well as methods of making and using such compositions.